Literature DB >> 6179819

Successful treatment of HBs and HBeAg positive chronic liver disease: prolonged inhibition of viral replication by highly soluble adenine arabinoside 5'-monophosphate (ARA-AMP).

I V Weller, M F Bassendine, A Craxi, M J Fowler, J Monjardino, H C Thomas, S Sherlock.   

Abstract

In eight HBs and HBe antigen positive patients with chronic active liver disease, adenine arabinoside 5'-monophosphate (ARA-AMP) given, intravenously or intramuscularly, six or 12 hours, produced inhibition of viral replication. In five patients given a short course of therapy with 10 or 15 mg/kg/day this effect was transient and in two thrombocytopenia occurred. In three further consecutive cases given a longer course with 5 mg/kg/day after five days of the high dose, thrombocytopenia was not seen and inhibition of viral replication for up to 13 months occurred. These patients lost HBV-DNA polymerase activity, serum viral DNA and HBeAg, developed anti-HBe, and HBsAg concentrations decreased. A course of twice daily intramuscular ARA-AMP given for three to five weeks as an outpatient may be expected to produce a long-term reduction in infectivity.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6179819      PMCID: PMC1419747          DOI: 10.1136/gut.23.9.717

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  10 in total

1.  DNA and DNA polymerase in the core of the Dane particle of hepatitis B.

Authors:  W S Robinson
Journal:  Am J Med Sci       Date:  1975 Jul-Aug       Impact factor: 2.378

2.  Antiviral treatment of chronic hepatitis B virus infection: improvement in liver disease with interferon and adenine arabinoside.

Authors:  G H Scullard; L L Andres; H B Greenberg; J L Smith; V K Sawhney; E A Neal; A S Mahal; H Popper; T C Merigan; W S Robinson; P B Gregory
Journal:  Hepatology       Date:  1981 May-Jun       Impact factor: 17.425

3.  Natural history of liver disease in chronic hepatitis B surface antigen carriers. Survey of 100 patients from Great Britain.

Authors:  L A Viola; I G Barrison; J C Coleman; F J Paradinas; J L Fluker; B A Evans; I M Murray-Lyon
Journal:  Lancet       Date:  1981-11-21       Impact factor: 79.321

4.  Effect of vidarabine on chronic hepatitis B virus infection.

Authors:  R B Pollard; J L Smith; A Neal; P B Gregory; T C Merigan; W S Robinson
Journal:  JAMA       Date:  1978-04-21       Impact factor: 56.272

5.  A radioimmunoassay for HBcAg in the sera of HBsAg carriers: serum HBcAg, liver HBcAg immunofluorescence as markers of chronic liver disease.

Authors:  M Rizzetto; J W Shih; G Verme; J L Gerin
Journal:  Gastroenterology       Date:  1981-06       Impact factor: 22.682

6.  Seroconversion from hepatitis B e antigen to anti-HBe in chronic hepatitis B virus infection.

Authors:  G Realdi; A Alberti; M Rugge; F Bortolotti; A M Rigoli; F Tremolada; A Ruol
Journal:  Gastroenterology       Date:  1980-08       Impact factor: 22.682

7.  Quantitative estimation of proteins by electrophoresis in agarose gel containing antibodies.

Authors:  C B Laurell
Journal:  Anal Biochem       Date:  1966-04       Impact factor: 3.365

8.  Type B hepatitis: the infectivity of blood positive for e antigen and DNA polymerase after accidental needlestick exposure.

Authors:  H J Alter; L B Seeff; P M Kaplan; V J McAuliffe; E C Wright; J L Gerin; R H Purcell; P V Holland; H J Zimmerman
Journal:  N Engl J Med       Date:  1976-10-21       Impact factor: 91.245

9.  HBsAg-positive chronic liver disease: inhibition of DNA polymerase activity by vidarabine.

Authors:  R G Chadwick; M F Bassendine; E M Crawford; H C Thomas; S Sherlock
Journal:  Br Med J       Date:  1978-08-19

10.  Adenine arabinoside therapy in HBsAg-positive chronic liver disease: a controlled study.

Authors:  M F Bassendine; R G Chadwick; J Salmeron; U Shipton; H C Thomas; S Sherlock
Journal:  Gastroenterology       Date:  1981-05       Impact factor: 22.682

  10 in total
  15 in total

1.  Randomised controlled trial of adenine arabinoside 5'-monophosphate (ARA-AMP) in chronic hepatitis B virus infection.

Authors:  I V Weller; A S Lok; A Mindel; P Karayiannis; S Galpin; J Monjardino; S Sherlock; H C Thomas
Journal:  Gut       Date:  1985-07       Impact factor: 23.059

2.  Antiviral treatment in chronic infection with hepatitis B virus.

Authors:  G Alexander; R Williams
Journal:  Br Med J (Clin Res Ed)       Date:  1986-04-05

3.  Activities of arabinosyladenine monophosphate and 9-(1,3-dihydroxy-2-propoxymethyl)guanine against ground squirrel hepatitis virus in vivo as determined by reduction in serum virion-associated DNA polymerase.

Authors:  D F Smee; S S Knight; A E Duke; W S Robinson; T R Matthews; P L Marion
Journal:  Antimicrob Agents Chemother       Date:  1985-02       Impact factor: 5.191

4.  In vitro and in vivo comparison of the abilities of purine and pyrimidine 2',3'-dideoxynucleosides to inhibit duck hepadnavirus.

Authors:  B Lee; W X Luo; S Suzuki; M J Robins; D L Tyrrell
Journal:  Antimicrob Agents Chemother       Date:  1989-03       Impact factor: 5.191

5.  Antiviral treatment of chronic hepatitis B virus infection.

Authors:  D M Novick; H C Thomas
Journal:  J R Soc Med       Date:  1984-12       Impact factor: 5.344

6.  Formulation of a stable vidarabine phosphate injection.

Authors:  M S Kwee; L M Stolk
Journal:  Pharm Weekbl Sci       Date:  1984-06-22

7.  Relationship between HBV-specific DNA polymerase and HBe antigen/antibody system in chronic HBV infection: factors determining selection of patients and outcome of antiviral therapy.

Authors:  A Craxi; I V Weller; M F Bassendine; M J Fowler; J Monjardino; H C Thomas; S Sherlock
Journal:  Gut       Date:  1983-02       Impact factor: 23.059

8.  Psychosocial impact of chronic infection with hepatitis B virus on British patients.

Authors:  A S Lok; D J van Leeuwen; H C Thomas; S Sherlock
Journal:  Genitourin Med       Date:  1985-08

9.  Preliminary trial of recombinant fibroblast interferon in chronic hepatitis B virus infection.

Authors:  M Eisenberg; S Rosno; G Garcia; M W Konrad; P B Gregory; W S Robinson; T C Merigan
Journal:  Antimicrob Agents Chemother       Date:  1986-01       Impact factor: 5.191

10.  Comparison of properties of woodchuck hepatitis virus and human hepatitis B virus endogenous DNA polymerases.

Authors:  O Hantz; T Ooka; L Vitvitski; C Pichoud; C Trepo
Journal:  Antimicrob Agents Chemother       Date:  1984-02       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.